Phase I study of intermittent and chronomodulated oral therapy with capecitabine in patients with advanced and/or metastatic cancer

BACKGROUND: The combination of capecitabine and gemcitabine at Fixed Dose Rate (FDR) has been demonstrated to be well tolerated, with apparent efficacy in patients with advanced cancers. FDR gemcitabine infusion leads to enhanced intracellular accumulation of drug and possible augmented clinical eff...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Santini, Daniele, Vincenzi, Bruno, Schiavon, Gaia, La Cesa, Annalisa, Gasparro, Simona, Vincenzi, Angelo, Tonini, Giuseppe
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2006
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC1402306/
https://ncbi.nlm.nih.gov/pubmed/16504126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-6-42
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares